Claims

[Claim 1]

Use of at least one bacterium having an anti-ringworm action selected from the group consisting of a strain of Staphylococcus hominis, a strain of Staphylococcus haemolyticus, and a strain of Staphylococcus warneri, in the manufacture of a composition for treating ringworm,

wherein the strain of Staphylococcus warneri includes Staphylococcus warneri ATCC27836.

[Claim 2]

The use according to claim 1, comprising the strain of Staphylococcus hominis.

[Claim 3]

The use according to claim 2, wherein the strain of Staphylococcus hominis has 16s rDNA including a nucleotide sequence of SEQ ID NO: 1 or 16s rDNA including a nucleotide sequence having 95% or more of identity to SEQ ID NO: 1 and has an anti-ringworm action.

[Claim 4]

The use according to claim 2, wherein the strain of Staphylococcus hominis includes at least one selected from the group consisting of Staphylococcus hominis ATCC27844, Staphylococcus hominis ATCC27845, and Staphylococcus hominis ATCC700236.

[Claim 5]

The use according to claim 1, wherein the composition comprises the strain of Staphylococcus haemolyticus.

[Claim 6]

The use according to claim 5, wherein the strain of Staphylococcus haemolyticus has a 16s rDNA including a nucleotide sequence of SEQ ID NO: 10 or a 16s rDNA including a nucleotide sequence having 95% or more of identity to SEQ ID NO: 10, and has an anti-ringworm action.

[Claim 7]

The use according to claim 5, wherein the strain of Staphylococcus haemolyticus includes at least one selected from the group consisting of Staphylococcus haemolyticus ATCC29970, Staphylococcus haemolyticus ATCC700564, and Staphylococcus haemolyticus ATCC29969.

[Claim 8]

The use according to claim 1, wherein the composition comprises the strain of Staphylococcus warneri.

[Claim 9]

The use according to any one of claims 1 to 8, wherein a causative fungus of the ringworm includes a fungus of the genus Trichophyton.

[Claim 10]

The use according to claim 9, wherein the causative fungus of the ringworm includes at least one selected from the group consisting of a fungal strain of Trichophyton rubrum, a fungal strain of Trichophyton mentagrophytes, and a fungal strain of Trichophyton tonsurans.

[Claim 11]

The use according to any one of claims 1 to 8, wherein the composition is an external preparation.

[Claim 12]

A method for producing a composition for treating ringworm, the method

comprising:

a step (1) of collecting and culturing a bacterial flora from at least one of a malleolus and a foot sole of a human;

a step (2) of isolating and culturing the bacterial flora cultured in the step (1) to obtain a candidate bacterium;

a step (3) of evaluating an anti-ringworm fungal action of the candidate bacterium to identify a bacterium having an anti-ringworm fungal action; and

a step (4) of preparing a composition for treating ringworm including the bacterium having an anti-ringworm fungal action;

wherein the bacterium having an anti-ringworm fungal action includes at least one selected from the group consisting of a strain of Staphylococcus hominis, a strain of Staphylococcus haemolyticus, and a strain of Staphylococcus warneri,

wherein the strain of Staphylococcus warneri includes Staphylococcus warneri ATCC27836.